DS-3032b for Relapsed and/or Refractory (RR) Myeloma

This trial is open and accepting eligible patients.

Trial Overview

This is a 2 part study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of DS-3032b that can be given to patients with MM. The goal of Part 2 of this clinical research study is to continue to study the safety of the highest tolerable dose found in Part 1 of the study.

What is the phase of this trial?

Phase 1 what does this mean

What type of trial is this?

This is an interventional trial. This type of trial actively treats your myeloma.

What treatments are used in this trial?
  • DS-3032b
Trial Locations

There are 1 trial site around the United States.
Find the closest trial site.

How many patients will participate in this trial?

Approximately 40 patients will be enrolled in this study.

Who is sponsoring this trial?

MD Anderson Cancer Center

SparkCures Trial Identifiers

MM-0765 , NCT02579824 what is this

1 US location

Am I Eligible For This Trial?

All clinical trials provide reasons that patients may or may not be able to join called 'eligibility criteria'. The following is a high-level eligibility criteria provided by the sponsor of this trial. Additional eligibility criteria may apply.

Trial Contact Information

Trial locations are sorted by state. Enter your zip code to sort by closest distance.


MD Anderson Cancer Center

(The University of Texas)

1515 Holcombe Boulevard, Houston, TX 77030

This site is open and accepting eligible patients.

There is 1 active US location.